Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02192359
Recruitment Status : Recruiting
First Posted : July 16, 2014
Last Update Posted : May 3, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center

Brief Summary:
This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come back. Placing genetically modified neural stem cells into brain tumor cells may make the tumor more sensitive to irinotecan hydrochloride. Irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboxylesterase-expressing allogeneic neural stem cells and irinotecan hydrochloride may be a better treatment for high-grade gliomas.

Condition or disease Intervention/treatment Phase
Adult Anaplastic Astrocytoma Adult Anaplastic Oligoastrocytoma Adult Anaplastic Oligodendroglioma Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor Glioma Biological: carboxylesterase-expressing allogeneic neural stem cells Drug: irinotecan hydrochloride Other: laboratory biomarker analysis Other: pharmacological study Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To define the recommended phase II doses (RP2D) of intracranially administered hCE1m6-NSCs (carboxylesterase-expressing allogeneic neural stem cells) in combination with intravenous irinotecan in patients with recurrent high grade glioma.

SECONDARY OBJECTIVES:

I. To describe the relationship between hCE1m6-NSC dose and SN-38 (liposomal SN-38) concentrations in brain interstitium.

II. To characterize the relationship between intracerebral and systemic concentrations of irinotecan (irinotecan hydrochloride) and SN-38.

III. To investigate the biologic activity of hCE1m6 NSCs by comparing SN-38 concentrations in the brain after treatment with hCE1m6-NSCs and irinotecan versus irinotecan alone.

IV. To assess for possible development of adenovirally transduced neural stem cell (NSC) immunogenicity after first exposure and with repeat doses of NSCs.

V. To describe the clinical benefit (defined as stable disease, partial response, or complete response) in patients who receive treatment with repeat cycles of NSCs and irinotecan.

VI. To determine, at time of autopsy, the fate of the NSCs.

OUTLINE: This is a dose-escalation study of carboxylesterase-expressing allogeneic neural stem cells.

Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride intravenously (IV) over 90 minutes on days 3 and 17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 3 and 6 months and then annually thereafter for 15 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 53 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas
Study Start Date : March 7, 2016
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020


Arm Intervention/treatment
Experimental: Treatment (hCE1m6-NSCs and irinotecan hydrochloride)
Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride IV over 90 minutes on days 3 and 17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Biological: carboxylesterase-expressing allogeneic neural stem cells
Given intracranially
Other Names:
  • CE-secreting allogeneic NSCs
  • hCE1m6-NSC

Drug: irinotecan hydrochloride
Given IV
Other Names:
  • Campto
  • Camptosar
  • CPT-11
  • irinotecan
  • U-101440E

Other: laboratory biomarker analysis
Correlative studies

Other: pharmacological study
Correlative studies
Other Name: pharmacological studies




Primary Outcome Measures :
  1. Incidence of dose limiting toxicities (DLTs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: 28 days ]
    Tables will be created to summarize all toxicities and side effects by dose, course, organ severity (by NCI CTCAE version 4.0), and attribution. Rates and associated 95% Clopper Pearson confidence limits will be estimated for DLTs.

  2. Incidence of all attributable toxicities graded according to the NCI CTCAE version 4.0 [ Time Frame: Up to 30 days after completion of study treatment ]
    Tables will be created to summarize all toxicities and side effects by dose, course, organ severity (by NCI CTCAE version 4.0), and attribution.


Secondary Outcome Measures :
  1. Pharmacokinetics parameters, including maximum concentration and area under the curve of irinotecan and SN-38 in dialysate and plasma [ Time Frame: Pre-dose, at 90 minutes (just prior to the end of the infusion), and then at 30 minutes, 1, 2, 4, 8, 24, and 48 hours after the end of the infusion ]
    Pharmacokinetic data from patients who undergo intracerebral microdialysis will be summarized using descriptive statistics and graphical methods. The biologic activity of the hCE1m6-NSCs will be assessed using a one-sided two-sample t test. Regression analysis will be used to assess the relationship between hCE1m6-NSC dose and SN-38 concentrations in brain interstitium using microdialysis data from the patients treated with the initial NSC dose and from the patients in the expansion cohort treated with the highest NSC dose.

  2. Development of NSC immunogenicity after first and repeat exposures [ Time Frame: Up to 15 years ]
    Will be summarized using descriptive statistics and graphical methods.

  3. Clinical benefit, defined by tumor response based on MRI results [ Time Frame: Up to 15 years ]
    Rates and associated 95% Clopper Pearson confidence limits will be estimated for clinical benefit at the recommended phase II dose.

  4. Fate of the NSCs, defined by NSC persistence [ Time Frame: Up to 15 years ]
    Will be summarized using descriptive statistics and graphical methods



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must be able to understand and be willing to sign a written informed consent document
  • Participant must be willing to comply with study and/or follow-up procedures
  • Karnofsky performance status >= 70%
  • Life expectancy of >= 3 months
  • Histologically-confirmed diagnosis of a grade III or IV glioma (including glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma), or has a prior, histologically-confirmed, diagnosis of a grade II glioma and now has radiographic findings consistent with a high-grade glioma (grade III or IV)
  • Imaging studies show evidence of recurrent tumor(s); if a patient is going to be enrolled to dose level two or higher, the patient must have a component of supratentorial disease (so as to enable placement of a Rickham reservoir/catheter) that is amenable to resection or biopsy
  • High-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide
  • Participant must be in need of a craniotomy for tumor resection or a stereotactic brain biopsy for the purpose of diagnosis or differentiating between tumor progression versus treatment-induced effects following radiation therapy +/- chemotherapy
  • Based on the neurosurgeon's judgment, there is no anticipated physical connection between the post-resection tumor cavity and the cerebral ventricles
  • Neurosurgeon finds the prospective participant is able to undergo neurosurgery
  • Any number of prior therapies is permitted; from the start of study treatment, the following time periods must have elapsed: 6 weeks from nitrosourea-containing chemotherapy, 4 weeks from non-nitrosourea-containing cytotoxic chemotherapy (except 23 days from last daily dose of temozolomide taken in a 5 of 28 day regimen), and 2 weeks from last dose of a targeted agent (except 4 weeks for bevacizumab); there is no time period requirement for prior radiation therapy
  • Any clinically significant toxicity from prior therapy must have improved to grade 0 or grade 1
  • Absolute neutrophil count (ANC) >= 1,500 cells/ul
  • Platelets > 100,000 cells/ul
  • Total bilirubin =< 2.0 mg/dl
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 4 times institutional upper limit of normal
  • Serum creatinine =< 1.5 x the institutional upper limit of normal
  • Homozygous negative for the UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT 1A1)*28 allele
  • Absence anti-human leukocyte antigen (HLA) antibodies specific for HLA class I antigens expressed by the coagulation factor III (thromboplastin, tissue factor) (F3).cytosine deaminase (CD).carboxylesterase (CE) NSCs
  • Negative serum pregnancy test (women of childbearing potential only)
  • Agreement by females of childbearing potential and sexually active males to use an effective method of contraception while participating in this study; women of childbearing potential must have a negative pregnancy test < 2 weeks prior to registration

Exclusion Criteria:

  • Prior therapy with neural stem cells
  • Use of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers including hepatic enzyme-inducing anticonvulsants (phenytoin, fosphenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) within 2 weeks prior to start of study treatment
  • Use of moderate to strong CYP3A4 inhibitors within 2 weeks prior to start of study treatment
  • Use of drugs known to inhibit UGT1A1, such as atazanir, gemfibrozil, indinavir, or ketoconazole, within 2 weeks prior to start of study treatment
  • Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids, such as systemic cyclosporine and tacrilomus; consult principal investigator for questions, including necessary washout period for the specific drug
  • Flucytosine within 2 weeks prior to start of study treatment
  • Use of herbal medications
  • Current use (or planned use during the treatment period) of other investigational agents, or biological, chemotherapy, radiation or other anti-tumor therapy
  • Patient has known human immunodeficiency virus (HIV) or hepatitis C infection; baseline testing for HIV or hepatitis C is not required
  • Prospective participant is unable to undergo a magnetic resonance imaging (MRI) with contrast agent
  • Known chronic or active viral infections of the central nervous system (CNS)
  • Clinically significant uncontrolled illness
  • Active infection requiring antibiotics
  • Diagnosis of Gilbert's disease
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan
  • Known sensitivity to any of the products to be administered during dosing
  • Any other active malignancy
  • Pregnant women and women who are lactating
  • Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the safety monitoring requirements and completion of treatment according to this protocol
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02192359


Locations
Layout table for location information
United States, California
City of Hope Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Jana L. Portnow    800-826-4673      
Principal Investigator: Jana L. Portnow         
Sponsors and Collaborators
City of Hope Medical Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Jana Portnow City of Hope Medical Center

Layout table for additonal information
Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT02192359     History of Changes
Other Study ID Numbers: 14108
NCI-2014-01463 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
14108 ( Other Identifier: City of Hope Medical Center )
R01CA198076 ( U.S. NIH Grant/Contract )
First Posted: July 16, 2014    Key Record Dates
Last Update Posted: May 3, 2019
Last Verified: May 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Glioblastoma
Glioma
Astrocytoma
Gliosarcoma
Oligodendroglioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Irinotecan
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents